NFKB1 and type 2 diabetes mellitus: Taken together, our findings reveal for the first time how T2D-related glucolipotoxicity induces dysfunction in SCs, and also demonstrate the remarkable efficacy of GLP-1 RA Liraglutide in increasing antioxidant defense capacity, reducing NFκB-mediated inflammation, and improving physiological function.